Search

Displaying results 3771 - 3780 of 5895 in total
  1. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication and eventually cell death.

  2. Drug

    IMM-101

    go.drugbank.com/drugs/DB15850
    Investigational

    Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. … It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023].

  3. Drug

    Nomacopan

    go.drugbank.com/drugs/DB14991
    Investigational

    Nomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).

  4. Drug

    Brolamfetamine

    go.drugbank.com/drugs/DB01484
    ExperimentalIllicit

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    AeroLEF

    go.drugbank.com/drugs/DB05000
    Investigational

    AeroLEF™ is in development for the treatment of moderate to severe pain, including cancer pain. … AeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia

  6. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  7. Drug

    N-Methylmesoporphyrin

    go.drugbank.com/drugs/DB01911
    Experimental

    This compound belongs to the porphyrins. … This medication is known to target ferrochelatase.

  8. Drug

    Alphaprodine

    go.drugbank.com/drugs/DB13160
    ExperimentalIllicit

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  10. Drug

    Cedirogant

    go.drugbank.com/drugs/DB18951
    Investigational

    Cedirogant is under investigation in clinical trial NCT05044234 (A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis